Ligand Reports Second Quarter 2016 Financial Results
Conference Call Begins at 9:00 a.m. Eastern Time Today
SAN DIEGO--
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported
financial results for the three and six months ended June 30, 2016, and
provided an operating forecast and program updates. Ligand
management will host a conference call today beginning at 9:00 a.m.
Eastern time to discuss this announcement and answer questions.
“The past few months have been very active and rewarding with excellent
revenue reports from our key licensees and important clinical,
regulatory and commercial accomplishments by our partners,” said John
Higgins, Chief Executive Officer of Ligand. “Royalties are up nearly 50%
over a year ago, driven by significant increases for Promacta®
and Kyprolis®. One of our licensed products with the highest
royalty rate is EVOMELA™, and we are pleased to see its approval and
commercial launch over the past few months. The OmniAb™ platform
technology we acquired early this year continues to be validated with
new and expanded licensing agreements, and adds considerable value in
addition to our growing roster of Captisol®-enabled programs.
We now have more than 150 shots-on-goal, or fully funded programs
partnered or licensed with other companies.”
Second Quarter 2016 Financial Results
Total revenues for the second quarter of 2016 were $19.5 million,
compared with $18.4 million for the same period in 2015. Royalty
revenues were $9.8 million, compared with $6.6 million for the same
period in 2015 primarily due to higher royalties from Promacta®
and Kyprolis®. Material sales were $3.9
million, compared with $10.7 million for the same period in 2015 due to
timing of Captisol® purchases for use in
clinical trials and commercial products. License and milestone revenues
were $5.9 million, compared with $1.1 million for the same period in
2015 due primarily to the timing of milestones and upfront license fees.
Cost of goods sold was $0.7 million for the second quarter of 2016,
compared with $2.6 million for the same period in 2015 due to the timing
and mix of Captisol sales. Amortization of intangibles was $2.7 million,
compared with $0.6 million for the same period in 2015 due primarily to
additional amortization of intangibles related to the acquisition of
OMT. Research and development expense was $4.5 million, compared with
$3.4 million for the same period of 2015 as a result of timing of
spending on internal development programs and non-cash stock-based
compensation expense. General and administrative expense was $6.9
million, compared with $7.2 million for the same period in 2015.
GAAP net loss for the second quarter of 2016 was $5.8 million, or $0.28
per share, compared with GAAP net income for the same period of 2015 of
$23.6 million, or $1.11 per diluted share. GAAP net loss includes a $10
million non-cash write-down in the value of the Company’s equity
holdings of Viking, or $0.48 per share due to its ownership in Viking
being reduced from 49% to 33% as a result of Viking’s financing
completed during the second quarter. Currently, the Company records the
value of Viking shares using the Equity Method, which requires the
Company to estimate the dilution to its position upon Viking issuing new
shares to third-parties. Adjusted net income for the second quarter of
2016 was $10.8 million, or $0.50 per diluted share, compared with
adjusted net income for the same period in 2015 of $38.5 million, or
$1.85 per diluted share.
As of June 30, 2016, Ligand had cash, cash equivalents and short-term
investments of $107.0 million.
Year-to-Date Financial Results
Total revenues for the six months ended June 30, 2016 were $49.2
million, compared with $33.0 million for the same period in 2015.
Royalty revenues were $24.1 million, compared with $16.9 million for the
same period in 2015 primarily due to higher royalties from Promacta®
and Kyprolis®. Material sales were $9.2
million, compared with $14.4 million for the same period in 2015 due to
timing of Captisol® purchases for use in
clinical trials and commercial products. License and milestone revenues
were $15.8 million, compared with $1.7 million for the same period in
2015 due primarily to the timing of milestones and upfront license fees.
Cost of goods sold was $1.7 million for the six months ended June 30,
2016, compared with $3.7 million for the same period in 2015 due to the
timing and mix of Captisol® sales. Amortization
of intangibles was $5.2 million, compared with $1.2 million for the same
period in 2015 due primarily to additional amortization of intangibles
related to the acquisition of OMT. Research and development expense was
$8.5 million, compared with $6.8 million for the same period of 2015 as
a result of timing of spending on internal development programs and
non-cash stock-based compensation expense. General and administrative
expense was $13.7 million, compared with $13.2 million for the same
period in 2015 due to costs associated with OmniAb and non-cash
stock-based compensation expense.
GAAP net income for the six months ended June 30, 2016 was $0.8 million,
or $0.04 per diluted share, compared with GAAP net income for the same
period of 2015 of $24.3 million, or $1.16 per diluted share. GAAP net
income includes a $10 million non-cash write-down in the value of the
Company’s equity holdings of Viking, or $0.44 per share due to its
ownership in Viking being reduced as a result of Viking’s financing
completed during the second quarter. Adjusted net income for the six
months ended June 30, 2016 was $31.8 million, or $1.47 per diluted
share, compared with adjusted net income for the same period in 2015 of
$45.4 million, or $2.19 per diluted share.
Financial Forecast
The Company affirms expectations for full-year 2016 total revenues to be
between $115 million and $119 million, and adjusted earnings per diluted
share to be between $3.41 and $3.46. Second half total revenues are
projected to be in the range of $66 million to $70 million, and adjusted
earnings per share are projected to be in the range of $1.94 to $1.99.
The adjusted earnings per diluted share guidance excludes non-cash
stock-based compensation expense, non-cash debt-related costs,
amortization related to acquisitions, changes in contingent liabilities,
non-cash net losses of Viking Therapeutics equity, mark-to-market
adjustment for amounts owed to licensors, fair value adjustments to
Viking Therapeutics convertible note receivable and warrants, non-cash
tax benefit (expense), unissued shares related to the anti-dilutive
effect of second quarter 2016 GAAP net loss, unissued shares relating to
the Senior Convertible Note and adjustments for discontinued operations,
net of non-cash tax expense.
Second Quarter 2016 and Recent Business Highlights
Portfolio Program Progress
Promacta®/Revolade®
-
Novartis announced Q2 2016 net sales of Promacta®
(eltrombopag) of $158 million, a $27 million or 21% increase over Q1
2016. This is the largest quarter-over-quarter increase in net sales
and comes one year after Novartis’s acquisition of the product from
GSK in early 2015.
-
The European Commission approved Revolade® (eltrombopag), a
Novartis product, for the treatment of pediatric (age 1 and above)
chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients
who are refractory to other treatments (e.g., corticosteroids,
immunoglobulins). The approval includes the use of tablets as well as
a new oral suspension formulation of Revolade®, which is
designed for younger children who may not be able to swallow tablets.
Kyprolis® (carfilzomib), an
Amgen Product Utilizing Captisol
-
On July 3, 2016, Amgen announced that the European Commission approved
an expanded indication for Kyprolis® (carfilzomib), to be used in
combination with dexamethasone alone, for adult patients with multiple
myeloma who have received at least one prior therapy.
-
On July 4, 2016, Ono Pharmaceuticals, holder of Kyprolis®
(carfilzomib) marketing rights in Japan, announced approval in Japan
for treatment of patients with relapsed or refractory multiple myeloma.
-
On May 26, 2016, Amgen announced that the Kyprolis Global Economic
Model (K-GEM) was published in the Journal of Medical Economics
showing that in the United States, Kyprolis® (carfilzomib) in
combination with lenalidomide and dexamethasone is cost-effective
compared with lenalidomide and dexamethasone alone in patients with
relapsed or refractory multiple myeloma and demonstrated an
incremental cost-effectiveness ratio of $107,250 per Quality-Adjusted
Life Year.
Additional Pipeline and Partner Developments
-
Spectrum Pharmaceuticals announced that the FDA granted seven years of
Orphan Drug Exclusivity for EVOMELA™ for use as a high-dose
conditioning treatment prior to hematopoietic progenitor (stem) cell
transplantation in patients with multiple myeloma.
-
Coherus BioSciences announced data demonstrating the equivalence of
its etanercept biosimilar (CHS-0214) to Enbrel®
(etanercept), the reference product, with respect to efficacy as
measured by the primary endpoint, ACR20 at 24 weeks.
-
Sage Therapeutics presented data that expanded scientific, clinical
and burden-of-illness data for SAGE-547 at the 68th
American Academy of Neurology Annual Meeting. Data from the open-label
Phase 1/2 trial of SAGE-547 in super-refractory status epilepticus
(SRSE) demonstrated that the 77% key efficacy endpoint response rate
was not related to age, gender, ethnicity, co-morbid medical condition
or underlying antiepileptic or third-line agents. Additional data
presented illustrated that SRSE has a high burden of illness with
significant morbidity, lengthy hospitalizations and significant
utilization of ICU and overall hospital resources.
-
Oncobiologics announced that its Phase 3 clinical plan for ONS-3010
(Humira® biosimilar) received the first of its European
Union clinical trial authorization approvals, including in the United
Kingdom, Germany and Spain, for the biosimilarity study portion of the
Phase 3 clinical program.
-
Viking Therapeutics highlighted positive data from a Phase 1b trial of
VK2809 (TR Beta) in subjects with mild hypercholesterolemia at the 65th
Annual Scientific Session and Expo of the American College of
Cardiology.
-
Viking Therapeutics announced positive top-line results from a
proof-of-concept study of VK0214 in a mouse model of X-linked
adrenoleukodystrophy (X-ALD), showing that VK0214 rapidly reduced
plasma very long chain fatty acid levels by more than 25% in treated
animals compared with vehicle controls (p < 0.01).
-
Merrimack Pharmaceuticals announced that the FDA granted seribantumab
(MM-121) Fast Track designation for development in patients with
heregulin-positive, locally advanced or metastatic non-small cell lung
cancer (NSCLC) whose disease has progressed following immunotherapy.
-
Merrimack Pharmaceuticals announced initiation of a Phase 1 study of
MM-151 in combination with ONIVYDE® plus fluorouracil (5-FU) and
Leucovorin in patients with RAS wild-type metastatic colorectal
cancer, as well as the initiation of a biomarker-selected, multi-arm
Phase 1 study for MM-151/MM-121 in metastatic colorectal, NSCLC and
head and neck cancer that uses a combination of genetic and nongenetic
biomarkers to match patients to appropriate novel combinations of
investigational drug regimens based on their cancer's molecular
signature.
-
Millennium/Takeda highlighted Phase 1b data on pevonedistat +
chemotherapy at the 2016 ASCO meeting.
-
Opthea announced that the Phase 1 dose-escalation study of OPT-302 met
its primary objective demonstrating safety and tolerability as
monotherapy and in combination with the current wet AMD standard of
care Lucentis®. Opthea is currently recruiting patients for
its Phase 2a dose-expansion trial and expects data by the end of 2016.
-
Upsher-Smith announced that it commenced the first clinical study of
its CXCR4 antagonist USL311 in patients with advanced solid tumors,
triggering a $500,000 milestone payment to Ligand.
-
Marinus Pharmaceuticals announced that the FDA granted Orphan Drug
designation to ganaxalone IV for the treatment of status epilepticus
and that the company dosed the first subject in its Phase 1 clinical
trial for the program.
-
An OmniAb licensee broadened its access to the platform by adding
OmniFlic. Prior to the option exercise, this licensee’s access to the
OmniAb technology was limited to OmniRat.
-
Wuxi out-licensed China rights to an undisclosed IND-ready antibody it
discovered with the OmniAb platform and its sub-licensee will be
responsible for all future costs related to the program.
-
Eli Lilly added a drug candidate to its Captisol® platform
license and supply agreement, first entered into in December of 2011.
New Licensing Deals
-
Ligand announced a license agreement for its LTP technology with
Nucorion Pharmaceuticals, a venture-funded biotechnology company
focused on developing anti-cancer and anti-viral agents initially
directed to China, of which Ligand is a minority shareholder. Three
initial programs fall under the license: NUC-202, a targeted
anti-cancer analog for the treatment of hepatocellular carcinoma;
NUC-404, a targeted nucleotide analog for the treatment of hepatitis
B; and NUC-101, a targeted nucleotide analog for the treatment of
hepatitis C. Ligand is eligible to receive milestones in addition to
royalties ranging from 5% to 9% on future net sales of any approved
program.
-
Ligand announced a worldwide license agreement with Gilead Sciences
that allows Gilead to use the OmniAb platform to discover fully human
mono- and bispecific antibodies. Ligand is eligible to receive annual
access payments, milestone payments and royalties on future net sales
of any antibodies discovered under the license.
-
Ligand entered a worldwide license agreement with F-Star Biotechnology
Limited that allows F-Star to use the OmniAb platform to discover
fully human mono- and bispecific antibodies. Ligand is eligible to
receive annual access payments, milestone payments and royalties on
future net sales of any antibodies discovered under the license.
Internal Glucagon Receptor Antagonist (GRA) Program
-
Ligand scientists gave an oral presentation on GRA at ENDO 2016 and
presented a poster at the Levine-Riggs Diabetes Research Symposium,
which highlighted data from the Phase 1b trial demonstrating that GRA
significantly reduced fasting and post-prandial glucose in subjects
with type 2 diabetes. Ligand expects to initiate a Phase 2 trial for
the program in Q3 2016.
Recent Acquisitions
-
In May 2016, Ligand acquired economic rights to multiple programs
owned by CorMatrix. Ligand paid $17.5 million to receive a portion of
revenue from CorMatrix’s existing marketed products and will have the
right to receive future royalties from potential future products.
Adjusted Financial Measures
The adjusted financial measures discussed above and in the tables below
for the three and six months ended June 30, 2016 and 2015 exclude
non-cash stock-based compensation expense, non-cash debt-related costs,
amortization related to acquisitions, changes in contingent liabilities,
non-cash net losses of Viking Therapeutics equity, mark-to-market
adjustment for amounts owed to licensors, fair value adjustments to
Viking Therapeutics convertible note receivable and warrants, non-cash
tax benefit (expense), unissued shares related to the anti-dilutive
effect of second quarter 2016 GAAP net loss, unissued shares relating to
the Senior Convertible Note and adjustments for discontinued operations,
net of non-cash tax expense.
Management has presented net income, net income per share in accordance
with GAAP and on an adjusted basis. Ligand believes the presentation of
adjusted financial measures provides useful supplementary information to
investors and reflects amounts that are more closely aligned with the
cash profits for the period. Ligand uses these adjusted financial
measures in connection with its own budgeting and financial planning.
These adjusted financial measures are in addition to, and not a
substitute for, or superior to, measures of financial performance
prepared in conformity with GAAP.
Conference Call
Ligand management will host a conference call today beginning at 9:00
a.m. Eastern time (6:00 a.m. Pacific time) to discuss this announcement
and answer questions. To participate via telephone, please dial (877)
407-4019 from the U.S. or (201) 689-8337 from outside the U.S., using
the passcode “Ligand.” A webcast replay of the call will be available at www.ligand.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring
technologies that help pharmaceutical companies discover and develop
medicines. Our business model creates value for stockholders by
providing a diversified portfolio of biotech and pharmaceutical product
revenue streams that are supported by an efficient and low corporate
cost structure. Our goal is to offer investors an opportunity to
participate in the promise of the biotech industry in a profitable,
diversified and lower-risk business than a typical biotech company. Our
business model is based on doing what we do best: drug discovery,
early-stage drug development, product reformulation and partnering. We
partner with other pharmaceutical companies to leverage what they do
best (late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s Captisol®
platform technology is a patent-protected, chemically modified
cyclodextrin with a structure designed to optimize the solubility and
stability of drugs. OmniAb® is a patent-protected transgenic
animal platform used in the discovery of fully human mono-and bispecific
therapeutic antibodies. Ligand has established multiple alliances,
licenses and other business relationships with the world's leading
pharmaceutical companies including Novartis, Amgen, Merck, Pfizer,
Celgene, Gilead, Janssen, Baxter International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
Forward-Looking Statements
This news release contains forward-looking statements by Ligand that
involve risks and uncertainties and reflect Ligand's judgment as of the
date of this release. Words such as “plans,” “believes,” “expects,”
“anticipates,” and “will,” and similar expressions, are intended to
identify forward-looking statements. These forward-looking statements
include, without limitation, statements regarding: Ligand’s future
revenue growth, Ligand's outlook for Captisol orders, the timing of the
initiation or completion of clinical trials by Ligand and its partners,
the timing of review of clinical data by the FDA, expected value
creation for shareholders and guidance regarding second half and
full-year 2016 financial results. Actual events or results may differ
from Ligand's expectations. For example, Ligand may not receive expected
revenue from material sales of Captisol, expected royalties on partnered
products and research and development milestone payments. Ligand and its
partners may not be able to timely or successfully advance any
product(s) in its internal or partnered pipeline. In addition, there can
be no assurance that Ligand will achieve its guidance for 2016 or any
portion thereof or beyond, that Ligand's 2016 revenues will be at the
levels or be broken down as currently anticipated, that Ligand will be
able to create future revenues and cash flows by developing innovative
therapeutics, that results of any clinical study will be timely,
favorable or confirmed by later studies, that products under development
by Ligand or its partners will receive regulatory approval, that there
will be a market for the product(s) if successfully developed and
approved, or that Ligand's partners will not terminate any of its
agreements or development or commercialization of any of its products.
Further, Ligand may not generate expected revenues under its existing
license agreements and may experience significant costs as the result of
potential delays under its supply agreements. Also, Ligand and its
partners may experience delays in the commencement, enrollment,
completion or analysis of clinical testing for its product candidates,
or significant issues regarding the adequacy of its clinical trial
designs or the execution of its clinical trials, which could result in
increased costs and delays, or limit Ligand's ability to obtain
regulatory approval. Further, unexpected adverse side effects or
inadequate therapeutic efficacy of Ligand's product(s) could delay or
prevent regulatory approval or commercialization. Ligand may also not
receive expected payments from CorMatrix in the event CorMatrix’s net
sales do not meet our projections. In addition, Ligand may not be able
to successfully implement its strategic growth plan and continue the
development of its proprietary programs. The failure to meet
expectations with respect to any of the foregoing matters may reduce
Ligand's stock price. Additional information concerning these and other
risk factors affecting Ligand can be found in prior press releases
available at www.ligand.com
as well as in Ligand's public periodic filings with the Securities and
Exchange Commission available at www.sec.gov.
Ligand disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution
is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Other Disclaimers and Trademarks
The information in this press release regarding certain third-party
products and programs, including Promacta, a Novartis product and
Kyprolis, an Amgen product, comes from information publicly released by
the owners of such products and programs. Ligand is not responsible for,
and has no role in, the development of such products or programs.
Ligand owns or has rights to trademarks and copyrights that it uses in
connection with the operation of its business including its corporate
name, logos and websites. Other trademarks and copyrights appearing in
this press release are the property of their respective owners. The
trademarks Ligand owns include Ligand®, Captisol® and OmniAb®.
Solely for convenience, some of the trademarks and copyrights referred
to in this press release are listed without the ®, © and TM
symbols, but Ligand will assert, to the fullest extent under applicable
law, its rights to its trademarks and copyrights.
|
|
|
LIGAND PHARMACEUTICALS, INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
|
Six Months Ended June 30,
|
|
|
|
|
|
2016
|
|
|
|
2015
|
|
|
|
2016
|
|
|
|
2015
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties
|
|
|
|
$
|
9,754
|
|
|
|
|
$
|
6,606
|
|
|
|
|
$
|
24,144
|
|
|
|
|
$
|
16,893
|
|
|
Material sales
|
|
|
|
3,886
|
|
|
|
|
10,681
|
|
|
|
|
9,227
|
|
|
|
|
14,410
|
|
|
License fees, milestones and other revenues
|
|
|
|
5,881
|
|
|
|
|
1,131
|
|
|
|
|
15,798
|
|
|
|
|
1,717
|
|
|
Total revenues
|
|
|
|
19,521
|
|
|
|
|
18,418
|
|
|
|
|
49,169
|
|
|
|
|
33,020
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
|
720
|
|
|
|
|
2,600
|
|
|
|
|
1,675
|
|
|
|
|
3,673
|
|
|
Amortization of intangibles
|
|
|
|
2,681
|
|
|
|
|
594
|
|
|
|
|
5,206
|
|
|
|
|
1,188
|
|
|
Research and development
|
|
|
|
4,507
|
|
|
|
|
3,416
|
|
|
|
|
8,508
|
|
|
|
|
6,784
|
|
|
General and administrative
|
|
|
|
6,863
|
|
|
|
|
7,225
|
|
|
|
|
13,691
|
|
|
|
|
13,219
|
|
|
Non-continuing expenses
|
|
|
|
374
|
|
|
|
|
218
|
|
|
|
|
618
|
|
|
|
|
441
|
|
|
Total operating costs and expenses
|
|
|
|
15,145
|
|
|
|
|
14,053
|
|
|
|
|
29,698
|
|
|
|
|
25,305
|
|
|
Income from operations
|
|
|
|
4,376
|
|
|
|
|
4,365
|
|
|
|
|
19,471
|
|
|
|
|
7,715
|
|
|
Other expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense, net
|
|
|
|
(2,550
|
)
|
|
|
|
(2,119
|
)
|
|
|
|
(5,163
|
)
|
|
|
|
(5,541
|
)
|
|
Increase in contingent liabilities
|
|
|
|
(332
|
)
|
|
|
|
(7,274
|
)
|
|
|
|
(1,638
|
)
|
|
|
|
(7,277
|
)
|
|
Gain on deconsolidation of Viking
|
|
|
|
—
|
|
|
|
|
28,190
|
|
|
|
|
—
|
|
|
|
|
28,190
|
|
|
Loss from Viking
|
|
|
|
(11,138
|
)
|
|
|
|
(870
|
)
|
|
|
|
(12,743
|
)
|
|
|
|
(870
|
)
|
|
Total other expense, net
|
|
|
|
(14,020
|
)
|
|
|
|
17,927
|
|
|
|
|
(19,544
|
)
|
|
|
|
14,502
|
|
|
(Loss) income before income taxes
|
|
|
|
(9,644
|
)
|
|
|
|
22,292
|
|
|
|
|
(73
|
)
|
|
|
|
22,217
|
|
|
Income tax benefit (expense)
|
|
|
|
3,881
|
|
|
|
|
(265
|
)
|
|
|
|
187
|
|
|
|
|
(279
|
)
|
|
Loss (income) from continuing operations including noncontrolling
interests
|
|
|
|
$
|
(5,763
|
)
|
|
|
|
$
|
22,027
|
|
|
|
|
114
|
|
|
|
|
21,938
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discontinued operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of Oncology Product Line, net of tax
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
731
|
|
|
|
|
—
|
|
|
Net (loss) income:
|
|
|
|
$
|
(5,763
|
)
|
|
|
|
$
|
22,027
|
|
|
|
|
$
|
845
|
|
|
|
|
$
|
21,938
|
|
|
Less: net loss attributable to noncontrolling interests
|
|
|
|
—
|
|
|
|
|
(1,537
|
)
|
|
|
|
—
|
|
|
|
|
(2,380
|
)
|
|
Net (loss) income attributable to common
|
|
|
|
$
|
(5,763
|
)
|
|
|
|
$
|
23,564
|
|
|
|
|
$
|
845
|
|
|
|
|
$
|
24,318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic per share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations
|
|
|
|
$
|
(0.28
|
)
|
|
|
|
$
|
1.19
|
|
|
|
|
$
|
0.01
|
|
|
|
|
$
|
1.24
|
|
|
Discontinued operations
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.03
|
|
|
|
|
—
|
|
|
Net (loss) income
|
|
|
|
$
|
(0.28
|
)
|
|
|
|
$
|
1.19
|
|
|
|
|
$
|
0.04
|
|
|
|
|
$
|
1.24
|
|
|
Diluted per share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from continuing operations
|
|
|
|
$
|
(0.28
|
)
|
|
|
|
$
|
1.11
|
|
|
|
|
$
|
0.01
|
|
|
|
|
$
|
1.16
|
|
|
Discontinued operations
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
0.03
|
|
|
|
|
—
|
|
|
Net (loss) income
|
|
|
|
$
|
(0.28
|
)
|
|
|
|
$
|
1.11
|
|
|
|
|
$
|
0.04
|
|
|
|
|
$
|
1.16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares-basic
|
|
|
|
20,832
|
|
|
|
|
19,725
|
|
|
|
|
20,765
|
|
|
|
|
19,668
|
|
|
Weighted average number of common shares-diluted
|
|
|
|
20,832
|
|
|
|
|
21,276
|
|
|
|
|
22,615
|
|
|
|
|
20,953
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIGAND PHARMACEUTICALS, INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2016
|
|
|
|
December 31, 2015
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and short-term investments
|
|
|
|
$
|
106,953
|
|
|
|
|
$
|
200,219
|
|
Accounts receivable, net
|
|
|
|
9,966
|
|
|
|
|
6,170
|
|
Note receivable from Viking
|
|
|
|
3,207
|
|
|
|
|
4,782
|
|
Inventory
|
|
|
|
3,835
|
|
|
|
|
1,633
|
|
Other current assets
|
|
|
|
2,602
|
|
|
|
|
1,908
|
|
Total current assets
|
|
|
|
126,563
|
|
|
|
|
214,712
|
|
Deferred income taxes
|
|
|
|
161,076
|
|
|
|
|
216,564
|
|
Goodwill and other identifiable intangible assets
|
|
|
|
282,502
|
|
|
|
|
60,585
|
|
Investment in Viking
|
|
|
|
18,733
|
|
|
|
|
29,728
|
|
Commercial license rights
|
|
|
|
26,141
|
|
|
|
|
8,554
|
|
Other assets
|
|
|
|
1,784
|
|
|
|
|
399
|
|
Total assets
|
|
|
|
$
|
616,799
|
|
|
|
|
$
|
530,542
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
|
|
$
|
7,647
|
|
|
|
|
$
|
10,422
|
|
Current portion of contingent liabilities
|
|
|
|
5,337
|
|
|
|
|
10,414
|
|
2019 convertible senior notes, net
|
|
|
|
207,363
|
|
|
|
|
—
|
|
Total current liabilities
|
|
|
|
220,347
|
|
|
|
|
20,836
|
|
2019 convertible senior notes, net
|
|
|
|
—
|
|
|
|
|
201,985
|
|
Long-term portion of contingent liabilities
|
|
|
|
4,138
|
|
|
|
|
3,033
|
|
Other long-term liabilities
|
|
|
|
398
|
|
|
|
|
297
|
|
Total liabilities
|
|
|
|
224,883
|
|
|
|
|
226,151
|
|
Total Ligand Pharmaceuticals stockholders' equity
|
|
|
|
391,916
|
|
|
|
|
304,391
|
|
Total liabilities and stockholders' equity
|
|
|
|
$
|
616,799
|
|
|
|
|
$
|
530,542
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIGAND PHARMACEUTICALS INCORPORATED
ADJUSTED FINANCIAL MEASURES
(Unaudited, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30,
|
|
|
|
Six months ended June 30,
|
|
|
|
|
|
2016
|
|
|
|
2015
|
|
|
|
2016
|
|
|
|
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
|
|
$
|
(5,763
|
)
|
|
|
|
$
|
23,564
|
|
|
|
|
$
|
845
|
|
|
|
|
$
|
24,318
|
|
Non-cash stock-based compensation expense
|
|
|
|
4,240
|
|
|
|
|
3,760
|
|
|
|
|
8,359
|
|
|
|
|
6,675
|
|
Non-cash debt related costs
|
|
|
|
2,710
|
|
|
|
|
2,548
|
|
|
|
|
5,379
|
|
|
|
|
5,058
|
|
Amortization related to acquisitions
|
|
|
|
2,185
|
|
|
|
|
—
|
|
|
|
|
4,115
|
|
|
|
|
—
|
|
Increase in contingent liabilities
|
|
|
|
332
|
|
|
|
|
7,274
|
|
|
|
|
1,638
|
|
|
|
|
7,277
|
|
Loss from Viking (a)
|
|
|
|
11,138
|
|
|
|
|
870
|
|
|
|
|
12,743
|
|
|
|
|
870
|
|
Mark-to-market adjustment for investments owed to licensors
|
|
|
|
142
|
|
|
|
|
465
|
|
|
|
|
(78
|
)
|
|
|
|
1,164
|
|
Fair market value adjustment on Viking note and warrants
|
|
|
|
(326
|
)
|
|
|
|
—
|
|
|
|
|
(311
|
)
|
|
|
|
—
|
|
Non-cash tax benefit
|
|
|
|
(3,845
|
)
|
|
|
|
—
|
|
|
|
|
(150
|
)
|
|
|
|
—
|
|
Discontinued operations, net of non-cash tax expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(731
|
)
|
|
|
|
—
|
|
Adjusted net income
|
|
|
|
$
|
10,813
|
|
|
|
|
$
|
38,481
|
|
|
|
|
$
|
31,809
|
|
|
|
|
$
|
45,362
|
|
Diluted per-share amounts attributable to common shareholders:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
|
|
$
|
(0.28
|
)
|
|
|
|
$
|
1.11
|
|
|
|
|
$
|
0.04
|
|
|
|
|
$
|
1.16
|
|
Non-cash stock-based compensation expense
|
|
|
|
0.20
|
|
|
|
|
0.18
|
|
|
|
|
0.37
|
|
|
|
|
0.32
|
|
Non-cash debt related costs
|
|
|
|
0.13
|
|
|
|
|
0.12
|
|
|
|
|
0.24
|
|
|
|
|
0.24
|
|
Amortization related to acquisitions
|
|
|
|
0.10
|
|
|
|
|
—
|
|
|
|
|
0.18
|
|
|
|
|
—
|
|
Increase in contingent liabilities
|
|
|
|
0.02
|
|
|
|
|
0.34
|
|
|
|
|
0.07
|
|
|
|
|
0.35
|
|
Loss from Viking (a)
|
|
|
|
0.53
|
|
|
|
|
0.04
|
|
|
|
|
0.56
|
|
|
|
|
0.04
|
|
Mark-to-market adjustment for investments owed to licensors
|
|
|
|
0.01
|
|
|
|
|
0.02
|
|
|
|
|
—
|
|
|
|
|
0.06
|
|
Fair market value adjustment on Viking note and warrants
|
|
|
|
(0.02
|
)
|
|
|
|
—
|
|
|
|
|
(0.01
|
)
|
|
|
|
—
|
|
Non-cash tax benefit
|
|
|
|
(0.18
|
)
|
|
|
|
—
|
|
|
|
|
(0.01
|
)
|
|
|
|
—
|
|
Anti-dilutive effect of GAAP net loss share count adjustment
|
|
|
|
(0.05
|
)
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
2019 Senior Convertible Notes share count adjustment
|
|
|
|
0.03
|
|
|
|
|
0.04
|
|
|
|
|
0.06
|
|
|
|
|
0.02
|
|
Discontinued operations, net of non-cash tax expense
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(0.03
|
)
|
|
|
|
—
|
|
Adjusted net income
|
|
|
|
$
|
0.50
|
|
|
|
|
$
|
1.85
|
|
|
|
|
$
|
1.47
|
|
|
|
|
$
|
2.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP-Weighted average number of common shares-diluted
|
|
|
|
20,832
|
|
|
|
|
21,276
|
|
|
|
|
22,615
|
|
|
|
|
20,953
|
|
Shares excluded due to anti-dilutive effect on GAAP net loss
|
|
|
|
2,123
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
Less: 2019 Senior Convertible Notes share count adjustment
|
|
|
|
1,205
|
|
|
|
|
463
|
|
|
|
|
977
|
|
|
|
|
232
|
|
Adjusted weighted average number of common shares-diluted
|
|
|
|
21,750
|
|
|
|
|
20,813
|
|
|
|
|
21,638
|
|
|
|
|
20,721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) Loss from Viking reflects the Company’s share of Viking's net loss
of $1,162 and $2,767 for the three and six months ended June 30, 2016,
respectively, and the decrease in the book value of the Company's equity
method investment in Viking of $9,976 as a result of the Company's
decreased ownership percentage in Viking after Viking's financing.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160804005462/en/
Ligand Pharmaceuticals Incorporated
Todd Pettingill, 858-550-7500
investors@ligand.com
Twitter:
@Ligand_LGND
or
LHA
Bruce Voss, 310-691-7100
bvoss@lhai.com
Source: Ligand Pharmaceuticals Incorporated
Released August 4, 2016